Published • loading... • Updated
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
Summary by 247wallst.com
1 Articles
1 Articles
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
The post Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up appeared first on 24/7 Wall St.. Ionis Pharmaceuticals (IONS) fell 8.5% to $58.82 on July 9 after Phase 3 CARDIO-TTRansform trial of eplontersen failed primary efficacy in transthyretin amyloid cardiomyopathy. Ionis stock plummeted 21% in one week and 14% in one month, marking potentially the biggest single-day decline in over five years for the RNA-targeted developer. Alnyl…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
